Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Argenx Se Ads (ARGX)

Argenx Se Ads (ARGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,790,545
  • Shares Outstanding, K 47,008
  • Annual Sales, $ 92,490 K
  • Annual Income, $ -182,520 K
  • 60-Month Beta 1.22
  • Price/Sales 150.65
  • Price/Cash Flow N/A
  • Price/Book 8.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -2.55
  • Number of Estimates 8
  • High Estimate -1.98
  • Low Estimate -2.82
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
212.92 +17.49%
on 06/15/20
259.34 -3.54%
on 07/13/20
+35.06 (+16.30%)
since 06/12/20
3-Month
130.00 +92.44%
on 04/15/20
259.34 -3.54%
on 07/13/20
+111.22 (+80.04%)
since 04/14/20
52-Week
103.75 +141.13%
on 03/16/20
259.34 -3.54%
on 07/13/20
+110.93 (+79.67%)
since 07/12/19

Most Recent Stories

More News
argenx (ARGX): Strong Industry, Solid Earnings Estimate Revisions

argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

ARGX : 247.39 (-1.37%)
Biotech Stock Roundup: REGN's Stake Buyback, INO, NVAX's Coronavirus Updates & More

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.

REGN : 615.05 (-0.13%)
SNY : 51.50 (+1.10%)
NVAX : 101.50 (-2.70%)
INO : 25.16 (-1.80%)
ICPT : 42.69 (-1.02%)
ARGX : 247.39 (-1.37%)
argenx Up on Positive Data from Pivotal Efgartigimod Study

argenx's (ARGX) lead pipeline candidate, efgartigimod, meets primary endpoint in a pivotal study evaluating it in myasthenia gravis. A BLA is likely to be filed by the end of 2020.

JNJ : 146.75 (+1.06%)
HALO : 26.94 (-0.66%)
ABBV : 96.72 (-1.16%)
ARGX : 247.39 (-1.37%)
Halozyme (HALO) Q1 Earnings and Revenues Miss Estimates

Halozyme (HALO) reports wider-than-expected Q1 loss. Shares down.

JNJ : 146.75 (+1.06%)
RHHBY : 43.9800 (-0.48%)
HALO : 26.94 (-0.66%)
ARGX : 247.39 (-1.37%)
Why Earnings Season Could Be Great for argenx (ARGX)?

argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ARGX : 247.39 (-1.37%)
Here's Why Momentum Investors Will Love ARGENX SE-ADR (ARGX)

Does ARGENX SE-ADR (ARGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

ARGX : 247.39 (-1.37%)
argenx SE ADR to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 28, 2019 / argenx SE ADR (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 28, 2019 at 9:00 AM Eastern...

ARGX : 247.39 (-1.37%)
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology

argenx (Euronext & Nasdaq: ARGX) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that enables use by argenx of Halozyme's ENHANZE® drug delivery...

ARGX : 247.39 (-1.37%)
HALO : 26.94 (-0.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ARGX with:

Business Summary

argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands.

See More

Key Turning Points

2nd Resistance Point 263.16
1st Resistance Point 256.99
Last Price 247.39
1st Support Level 247.00
2nd Support Level 243.18

See More

52-Week High 259.34
Last Price 247.39
Fibonacci 61.8% 199.90
Fibonacci 50% 181.54
Fibonacci 38.2% 163.19
52-Week Low 103.75

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar